Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Size is valued at USD 5.4 Bn in 2023 and is predicted to reach USD 10.8 Bn by the year 2031 at a 9.3% CAGR during the forecast period for 2024-2031
Both liposomal and lipid nanoparticle systems are notable advancements in drug delivery technology, specifically for delivering therapeutic compounds that are challenging to administer due to stability or toxicity concerns. Their progress is constantly advancing as they tackle the difficulties of accurately focusing on and treating different ailments, particularly in the realm of personalized medicine and advanced medicines.
The enormous need for medicine on a global scale necessitates the consumption of pharmaceutical lipids, particularly liposomal medicines utilized in cancer treatment. Furthermore, the need for nanomedicine is rising because of the older population and the rise in chronic disorders. This is because nanoparticles have special properties like improved permeability and prolonged circulation, making them ideal for treating complex chronic ailments.
Nevertheless, the market expansion of the pharmaceutical industry's liposomal and lipid nanoparticle delivery system sales is hindered by stringent regulatory standards concerning safety and health. Additionally, the product's effectiveness in preventing fog in environments with significant temperature changes or high nanoparticle contract manufacturing is limited. These regulations have been implemented to ensure the quality and efficacy of medications due to the global expansion of the pharmaceutical industry.
In several nations, regulatory agencies have arisen to fulfill the legal needs of drug research. Furthermore, the inflow of R&D capital for creating and commercializing complicated pharmaceuticals via nanoparticle contract manufacturing was constrained by tight rules enacted by multiple governments. Due to the COVID-19 pandemic, which has affected the overall world market and forced the closure of number of factories to protect their personnel from contracting the virus, the expansion of the industry may be hindered.
The global market of liposomal and lipid nanoparticle drug delivery systems is categorized into type and end-user. As per the type segment, the market is segmented into liposome drugs and lipid nanoparticle drugs. By application, the market comprises hospitals, retail pharmacies, and Others.
The lipid nanoparticles liposomal and lipid nanoparticle drug delivery systems market is expected to hold a major global market share in 2023. Lipid nanoparticles are the most common type in the nanoparticle contract manufacturing industry because of their unique characteristics and wide range of uses. They are versatile enough to be used in various industries, the most notable being healthcare.
Hospitals dominates the segment because hospitals have saved countless lives. People with serious illnesses, such as cancer, neurological disorders, or catastrophic injuries, would benefit greatly from being there. Unfortunately, certain diseases do not have a cure. As a means of sustaining human life, hospitals have state-of-the-art facilities and technologies, especially in countries like the US, Germany, the U.K., China, and India.
The North American liposomal and lipid nanoparticle drug delivery systems market is expected to register the highest revenue share in the near future. This can be attributed to the rapid development of technology in underdeveloped regions. In addition, Europe is predicted to grow rapidly in the global market of liposomal and lipid nanoparticle drug delivery systems because of significant progress in materials science and nanotechnology. Innovation brought about by these breakthroughs has spurred nanoparticle manufacturing processes.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 5.4 Bn |
|
Revenue Forecast In 2031 |
USD 10.8 Bn |
|
Growth Rate CAGR |
CAGR of 9.37% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type and Application |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
|
Competitive Landscape |
Johnson & Johnson, Sun Pharmaceutical, CSPC, Teva, Fudan-Zhangjiang, Zydus Cadila (India), TTY Biopharma, Pacira, Luye Pharma, Leadiant Biosciences, Ipsen (France), Sayre Therapeutics, Alnylam, Bausch Health, Acrotech Biopharma, Takeda, Chiesi Farmaceutici, and Gilead Sciences. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Snapshot
Chapter 4. Global Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Type Estimates & Trend Analysis
5.1. by Type & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Type:
5.2.1. Liposomes Drugs
5.2.2. Lipid Nanoparticle Drugs
Chapter 6. Market Segmentation 2: by Application Estimates & Trend Analysis
6.1. by Application & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:
6.2.1. Hospital
6.2.2. Retail Pharmacy
6.2.3. Other
Chapter 7. Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031
7.1.2. North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
7.1.3. North America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
7.2. Europe
7.2.1. Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031
7.2.2. Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
7.2.3. Europe Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
7.3. Asia Pacific
7.3.1. Asia Pacific Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031
7.3.2. Asia-Pacific Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
7.3.3. Asia Pacific Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
7.4. Latin America
7.4.1. Latin America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031
7.4.2. Latin America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
7.4.3. Latin America Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
7.5. Middle East & Africa
7.5.1. Middle East & Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031
7.5.2. Middle East & Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031
7.5.3. Middle East & Africa Liposomal and Lipid Nanoparticle Drug Delivery Systems Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Johnson & Johnson (U.S.)
8.2.2. Sun Pharmaceutical (India)
8.2.3. CSPC (China)
8.2.4. Teva (Israel)
8.2.5. Fudan-Zhangjiang (China)
8.2.6. Zydus Cadila (India)
8.2.7. TTY Biopharma (Taiwan)
8.2.8. Pacira (U.S.)
8.2.9. Luye Pharma (China)
8.2.10. Leadiant Biosciences (U.S.)
8.2.11. Ipsen (France)
8.2.12. Sayre Therapeutics (Japan)
8.2.13. Alnylam (U.S.)
8.2.14. Bausch Health (U.S.)
8.2.15. Acrotech Biopharma (U.S.)
8.2.16. Takeda (Japan)
8.2.17. Chiesi Farmaceutici (Italy)
8.2.18. Gilead Sciences (U.S.)
8.2.19. Other Prominent Players
Liposomal and Lipid Nanoparticle Drug Delivery Systems Market By Type-
Liposomal and Lipid Nanoparticle Drug Delivery Systems Market By Application-
Liposomal and Lipid Nanoparticle Drug Delivery Systems Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
